Skip to main content
. Author manuscript; available in PMC: 2007 Aug 3.
Published in final edited form as: Exp Neurol. 2007 Mar 23;205(2):461–470. doi: 10.1016/j.expneurol.2007.03.013

Figure 2.

Figure 2

NAL treatment (50 mg/kg/day) increases MN survival in NSV-infected mice without altering virus tropism, replication, or clearance from the SC. (A) The loss of MN axons in lumbar ventral nerve roots among NAL-treated animals (broken line) was significantly reduced compared to untreated controls (solid line) at two time points examined (*p < 0.05, **p < 0.01). (B, C) Immunostaining for viral antigens showed selective staining of motor neurons in both saline-treated (B) and NAL-treated animals (C) in lumbar SC sections. Magnification 400x. (D) Replication and clearance of NSV from the lumbar SC of NAL-treated animals (broken line) was unchanged compared to saline-treated controls (solid line). Each point represents the mean ± SEM of the log10 PFU per gram of tissue from 3 animals. Viral growth curves were not statistically different from each other at any time point.